Although one dengue serotype is the most frequent in Brazil, epidemiological evidence shows that two other dengue serotypes are circulating in the country. At the moment, the only possible response to the epidemic is the mosquito vector control strategy, which is difficult to implement and maintain.
Given the above scenario, the development of a tetravalent dengue virus purified inactivated vaccine by Bio-Manguinhos/FIOCRUZ is relevant not only to Brazil but has become the focus of a collaborative effort by the international community. The vaccine’s complete development involves five phases: advance process exploration and pre-selection of the viral strains, confirmation of these viral strains, preclinical studies, definition of clinical parameters to support epidemiological and clinical studies, and preparation for clinical development.
The aim is to supply a vaccine for the Brazilian population and contribute to the goal of the National Immunization Program (PNI) to eradicate vaccine-preventable diseases in the country.